Heterotopic ossification: pharmacologic options.
Cullen
Nora
N
Toronto Rehabilitation Institute and Division of Physiatry, University of Toronto, Toranto, Ontario, Canada. cullen.nora@torontorehab.on.ca
Perera
Jerome
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001930:Brain Injuries / Q000150:complications*; D015232:Dinoprostone / Q000378:metabolism; D012968:Etidronic Acid / Q000627:therapeutic use; D006801:Humans; D009999:Ossification, Heterotopic / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D050071:Bone Density Conservation Agents; D015232:Dinoprostone; D012968:Etidronic Acid